, Tracking Stock Market Picks
Enter Symbol:

down 12.92 %

LEXICON PHARMACEUTCL (LXRX) rated Buy with price target $4 by Stifel Nicolaus

Posted on: Tuesday,  Jun 26, 2012  8:25 AM ET by Stifel Nicolaus

Stifel Nicolaus rated Buy LEXICON PHARMACEUTCL (NASDAQ: LXRX) on 06/26/2012, when the stock price was $13.93. Since
then, LEXICON PHARMACEUTCL has lost 12.92% as of 01/04/2016's recent price of $12.13.
If you would have followed this Stifel Nicolaus's recommendation on LXRX, you would have lost 12.92% of your investment in 1287 days.

Lexicon Pharmaceuticals, Inc. (Lexicon), is a biopharmaceutical company focused on discovering and developing treatments for human disease. The Company uses its proprietary gene knockout technology to identify and develop new drugs. In its Genome5000 program, Lexicon is utilizing its knowledge of the function of nearly 5,000 genes to identify a portfolio of drug targets. Lexicon has advanced multiple drug candidates into human clinical trials and has a diverse pipeline of drug targets behind its clinical programs with many compounds and antibodies in preclinical research. Lexicon is conducting clinical trials for four drug candidates, with its most advanced program in Phase II clinical trials.

Stifel Nicolaus research focuses on all market caps, but is a leader in small- and mid-cap research. The department is staffed predominately with industry professionals from outside Wall Street. In fact, approximately 50% of its analysts have hands-on work experience in the industry that they research. Stifel Nicolaus believes industry experience, its opportunistic approach, and broad market cap coverage drive excess returns and its award-winning franchise.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
6/26/2012 8:25 AM Buy
13.93 28.00
as of 12/31/2012
1 Week up  15.70 %
1 Month up  28.48 %
3 Months down  -4.74 %
1 YTD up  11.05 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy